2026 Diabetes Predictions: Retatrutide, Oral GLP-1s, Stem Cell Breakthroughs… and more!

Drs. Steve Edelman and Jeremy Pettus sit down to share their top predictions for the near future!

Together, they walk through emerging therapies for both type 1 and type 2 diabetes, focusing on developments that are no longer theoretical but actively moving through late-stage trials and regulatory review. The conversation covers disease-modifying treatments, next-generation medications, and technology advances that could meaningfully change daily diabetes management.

⏱️ TIMESTAMPS:
0:00 - Intro: The Golden Age of Diabetes
1:56 - T1D: Teplizumab (Tzield) for New Onset Patients
7:02 - T2D: The First Once-Daily Oral GLP-1 (Orforglipron)
9:27 - T2D: CagriSema (Supercharged Ozempic)
12:51 - T2D: Retatrutide (Triple Agonist & Muscle Preservation)
15:08 - T1D: Vertex Stem Cell Therapy & Cures
19:00 - T2D: Accessibility & Lower Drug Prices (Medicare)
21:00 - T1D: When will Type 1s get GLP-1s?
24:00 - T2D: Once-Weekly Basal Insulin (Icodec)
27:16 - Afrezza: New Dosing Guidelines
29:15 - T1D: Gene Therapy (Kriya) - No Immunosuppression?
33:00 - Tech: Continuous Ketone Monitors (CKM)
35:34 - T2D: Automated Insulin Delivery Updates

We also created an article on this topic, which you might want to read: https://tcoyd.org/2025/12/diabetes-pr...

✨ Subscribe for must-know updates, advocacy news, and technology breakthroughs that empower people with diabetes to live longer, healthier, and happier lives. Let's stay informed and take control together!

We've got tons of other great resources on how to live a long and healthy life with diabetes:
Website: https://tcoyd.org
Blog: https://tcoyd.org/blog/
Podcast: https://tcoydthepodcast.transistor.fm
Instagram: / tcoyd
Facebook: / tcoyd

Stay connected! Sign up for our monthly e-newsletter here: https://tcoyd.org/newsletter-subscribe/

Please consider helping TCOYD continue to improve the lives of those living with diabetes by supporting our educational programs: https://tcoyd.org/donate